[{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Core protein allosteric","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Bictegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Gilead"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase strand transfer\n","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"JNJ-73763989","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Janssen","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Janssen"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"CHAI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Emtricitabine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ CHAI","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ CHAI"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Tenofovir Alafenamide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Emtricitabine & tenofovir alafenamide is a generic equivalent of Descovy. This combination is NRT-inhibitor. It is indicated for HIV-1 Infection in adults & pediatric patients.

Brand Name : Descovy-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 31, 2024

Lead Product(s) : Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It is now approved for the treatment of HIV in pregnant adults.

Brand Name : Biktarvy

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 26, 2024

Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Vemlidy (tenofovir alafenamide) is approved for chronic hepatitis B in pediatric patients (6+ years) with compensated liver disease.

Brand Name : Vemlidy

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 28, 2024

Lead Product(s) : Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It is being evaluated for the treatment of HIV and Hepatitis B.

Brand Name : Biktarvy

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 06, 2024

Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It got extended approval for HIV with suppressed viral loads, pre-existing resistance.

Brand Name : Biktarvy

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 26, 2024

Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The partnership aims to accelerate the development of an investigational dispersible pediatric formulation containing Descovy (emtricitabine) and tenofovir alafenamide (F/TAF).

Brand Name : Descovy

Molecule Type : Small molecule

Upfront Cash : Undisclosed

July 13, 2023

Lead Product(s) : Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : CHAI

Deal Size : Undisclosed

Deal Type : Partnership

blank

07

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Tenofovir alafenamide accumulates more in peripheral blood mononuclear cells compared to red blood cells. Once activated, it acts with different mechanisms including the inhibition of viral polymerase, causing chain termination and the inhibition of vira...

Brand Name : Vemlidy-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 31, 2023

Lead Product(s) : Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Biktarvy is a combination of bictegravir which targets HIV-1 integrase thus inhibiting HIV virus replication, emtricitabine and tenofovir alafenamide which inhibits the activity of the HIV-1 reverse transcriptase resulting in DNA chain termination.

Brand Name : Biktarvy

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 14, 2023

Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The combination inhibits HIV-1 replication, in which dolutegravir inhibits HIV integrase and blocks the strand transfer step of retroviral DNA integration where emtricitabine and tenofovir alafenamide inhibits the activity of the HIV-1 reverse transcript...

Brand Name : Dolutegravir/Emtricitabine/Tenofovir Alafenamide-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 31, 2023

Lead Product(s) : Dolutegravir Sodium,Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available.

Brand Name : Biktarvy

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 29, 2022

Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank